

A pathogenic mechanism associated with myopathies and structural birth defects involves *TPM2*-directed myogenesis


Jennifer McA Dow, ... , Michael J. Greenberg, Aaron N. Johnson

JCI Insight. 2022;7(12):e152466. <https://doi.org/10.1172/jci.insight.152466>.

Research Article

Muscle biology

Graphical abstract



Find the latest version:

<https://jci.me/152466/pdf>



A pathogenic mechanism associated with myopathies and structural birth defects involves *TPM2*-directed myogenesis

Jennifer McAdow,¹ Shuo Yang,¹ Tiffany Ou,¹ Gary Huang,¹ Matthew B. Dobbs,² Christina A. Gurnett,^{3,4,5} Michael J. Greenberg,⁶ and Aaron N. Johnson¹

¹Department of Developmental Biology, Washington University in St. Louis, St. Louis, Missouri, USA. ²Paley Orthopedic and Spine Institute, West Palm Beach, Florida, USA. ³Department of Neurology, ⁴Department of Orthopedic Surgery, ⁵Department of Pediatrics, and ⁶Department of Biochemistry and Molecular Biophysics, Washington University in St. Louis, St. Louis, Missouri, USA.

Nemaline myopathy (NM) is the most common congenital myopathy, characterized by extreme weakness of the respiratory, limb, and facial muscles. Pathogenic variants in *Tropomyosin 2 (TPM2)*, which encodes a skeletal muscle-specific actin binding protein essential for sarcomere function, cause a spectrum of musculoskeletal disorders that include NM as well as cap myopathy, congenital fiber type disproportion, and distal arthrogryposis (DA). The in vivo pathomechanisms underlying *TPM2*-related disorders are unknown, so we expressed a series of dominant, pathogenic *TPM2* variants in *Drosophila* embryos and found 4 variants significantly affected muscle development and muscle function. Transient overexpression of the 4 variants also disrupted the morphogenesis of mouse myotubes in vitro and negatively affected zebrafish muscle development in vivo. We used transient overexpression assays in zebrafish to characterize 2 potentially novel *TPM2* variants and 1 recurring variant that we identified in patients with DA (V129A, E139K, A155T, respectively) and found these variants caused musculoskeletal defects similar to those of known pathogenic variants. The consistency of musculoskeletal phenotypes in our assays correlated with the severity of clinical phenotypes observed in our patients with DA, suggesting disrupted myogenesis is a potentially novel pathomechanism of *TPM2* disorders and that our myogenic assays can predict the clinical severity of *TPM2* variants.

Introduction

Tropomyosins are obligate actin binding proteins that form hetero- and homodimers (1). Head-to-tail tropomyosin polymers assemble along the length of actin filaments, and in the sarcomere tropomyosin regulates contractility by controlling the ability of thick filament myosin to access actin thin filaments (2). To initiate muscle contraction, Ca²⁺ released from the sarcoplasmic reticulum binds to sarcomeric troponin, which alters thin filament confirmation. The intermediate thin filament confirmation allows myosin to contact actin and further displace tropomyosin to drive maximal thin filament sliding and complete contraction (2).

Tropomyosin is encoded by 4 loci in humans (*TPM1*, *TPM2*, *TPM3*, and *TPM4*), with *TPM2* and *TPM3* being the predominant skeletal muscle isoforms (1). Pathogenic *TPM2* variants are causative of congenital skeletal muscle diseases, and much attention has been given toward understanding how *TPM2* variants disrupt sarcomere function. However, tropomyosin also functions outside of the sarcomere to regulate cytoskeletal changes that drive cell migration and cellular metastasis (3–5). Since skeletal muscle development depends on cytoskeletal dynamics to direct muscle precursor migration (6) and myofiber morphogenesis (7, 8), it is distinctly possible that *TPM2* variants adversely affect cytoskeletal dynamics prior to sarcomere assembly, which could disrupt overall muscle myogenesis.

Congenital diseases associated with *TPM2* include nemaline myopathy (NM) and cap myopathy (CM), which are both associated with extreme muscle weakness (hypotonia) (9–13). The diagnostic features for NM and CM are the presence of nemaline bodies and cap-like structures on muscle biopsy. Pathogenic *TPM2* variants are also causative of congenital fiber type disproportion (CFTD), in which highly oxidative type 1 myofibers are predominant and visibly hypotrophic (14). Patients with CFTD are also hypotonic.

Authorship note: JM and SY contributed equally to the manuscript.

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2022, McAdow et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Submitted: June 17, 2021

Accepted: May 13, 2022

Published: May 17, 2022

Reference information: *JCI Insight*. 2022;7(12):e152466.
<https://doi.org/10.1172/jci.insight.152466>.





Figure 1. TPM2 residues associated with pathogenic variants are conserved. (A) TPM2 conservation and sequence structure. TPM2 protein sequence divided into 7 quasi-repeats, split into α - and β -bands as described before (26). Actin-binding residues are colored blue. Vertical black lines show identical residues between the human (hs), Drosophila (dm), or zebrafish (dr) proteins; gray lines show similar residues. A total of 25 pathogenic TPM2 coding region variants have been reported (19). We identified 2 potentially novel variants (V129A and E139K) and 1 recurring variant (A155T) in patients with musculoskeletal birth defects. Variants affecting conserved residues are boxed in red; nonconserved pathogenic variants are boxed in black. **(B)** Conserved pathogenic variants disproportionately cluster to a single topographical position. Diagram showing the 7-amino acid heptad (a-g) of the TPM2 coiled-coil, as described (62). A subset of b and f residues binds actin (blue circles). There are 7 conserved pathogenic variants mapped to residues in position g.



A fourth congenital disease associated with TPM2 is distal arthrogyrosis (DA). The heterogeneity of DA clinical phenotypes has necessitated subtype classifications with hierarchical criteria (15). TPM2 variants are causative of DA type 1 (DA1) (16), which is characterized by contractures of the hands and feet, including permanently bent fingers (camptodactyly) and clubfoot (talipes equinovarus) (15). TPM2 variants are also associated with DA type 2B (DA2B) (17, 18), which is characterized by facial abnormalities in addition to contractures of the extremities (15). Patients with DA often show hypotonia (19, 20), suggesting skeletal muscle dysfunction contributes to the overall disease mechanism.

Table 1. Properties of pathogenic *TPM2* variants characterized in vivo

Variant	Diagnosis	Molecular phenotype	Reference
K7Del	DA, NM	Increased Ca ²⁺ sensitivity	9, 10, 19, 26
E41K	DA, NM	Reduced Ca ²⁺ sensitivity	11, 19, 29, 33, 63
K49Del	CM	Increased Ca ²⁺ sensitivity, reduced actin affinity	13, 33, 35
R91G	DA	Increased Ca ²⁺ sensitivity, reduced actin affinity	16, 64
E122K	Unspecified myopathy	Unknown	19, 21
R133P	CFTD	Unknown	19
R133W	DA, EVMPS, NM	Reduced Ca ²⁺ sensitivity	18, 22, 28, 32, 65
N202K	CM	Unknown	13, 66
V129A	Clubfoot	Unknown	This study
E139K	DA	Unknown	This study
A155T	DA	Unknown	48, this study

CM, cap myopathy; CFTD, congenital fiber type disproportion; DA, distal arthrogyposis; EVMPS, Escobar variant of multiple pterygium syndrome; NM, nemaline myopathy.

TPM2 variants are also causative of Escobar variant of multiple pterygium syndrome (EVMPS) (19, 21, 22). Patients with EVMPS show joint contractures similar to those reported for patients with DA, but EVMPS is differentiated from DA by the presence of webbing (pterygia) at the neck, elbows, or knees (23). It is important to note that hypotonia often extends to the diaphragm in patients carrying *TPM2* variants, which may require lifelong respiratory intervention (13, 14, 19). The broad spectrum of clinical phenotypes associated with *TPM2* mutations has obscured a clear understanding as to how pathogenic *TPM2* variants disrupt skeletal muscle form and function.

While the in vivo disease mechanisms that underlie *TPM2*-associated disorders are incompletely understood, the inheritance of *TPM2* congenital diseases follows an autosomal dominant pattern (9, 24). One notable exception is the pathogenic variant Q210*, which was shown to be autosomal recessive in a consanguineous family with EVMPS (25). A total of 30 pathogenic *TPM2* variants have been reported, and the variants themselves show a fairly even distribution along the protein (Figure 1A) (19). *TPM2* is composed of 7 quasi-repeats, each divided into 1 α -sheet and 1 β -sheet, with 1 residue per quasi-repeat binding actin (26). In addition to the quasi-repeats, *TPM2* forms a coiled-coil that follows the typical heptad repeat of 7 residues, labeled *a-g*, where *b* and *f* residues interact with actin and *g* residues are charged. Surprisingly, only 1 pathogenic variant changes an actin binding residue (K128E) (19), while 7 variants cluster to charged *g* positions (Figure 1B). The molecular genetics of *TPM2*-related disorders argues that pathogenic *TPM2* variants are dominant, gain-of-function mutations that indirectly disrupt tropomyosin-actin interactions.

Extensive biochemical studies have been used to understand the gain-of-function phenotypes *TPM2* variants induce. Thin filaments, or even entire muscle fibers, can be reconstituted in vitro to assay myosin-driven actin motility (26–32). Reconstituted thin filaments contain actin, tropomyosin, and troponin, such that actin motility can be measured in response to a Ca²⁺ gradient. Actin motility assays have shown that some *TPM2* variants increase Ca²⁺ sensitivity, causing maximum actin motility to be reached at comparatively low Ca²⁺ concentrations, while other variants reduce Ca²⁺ sensitivity (Table 1) (26, 32–34). The addition of fluorescence probes and proteins to actin motility assays reveals that the Ca²⁺ sensitivity of *TPM2* variants correlates with the ability of troponin and myosin to shift tropomyosin away from actin and that pathogenic substitutions alter tropomyosin flexibility (27–31). Since tropomyosin often exists as a heterodimer, *TPM2* variants likely act as gain-of-function mutations by altering Ca²⁺ sensitivity when dimerized with wild-type isoforms (28, 29, 35). Despite these extensive studies into the biochemical properties of *TPM2* mutations, pathogenic *TPM2* variants have rarely been characterized in vivo.

We set out to model *TPM2* congenital disorders in vivo, with the prediction that *TPM2* mutations would adversely affect muscle development and function. *TPM2* has been deleted in mice, and heterozygotes showed compromised lens regeneration (36). However, genome-edited *TPM2* variants have not been reported in any organism to our knowledge. A total of 28 pathogenic variants that affect the *TPM2* coding region have been reported, and we used transgenic overexpression in *Drosophila*, mammalian cell culture, and zebrafish embryos to study a representative collection of variants. Our studies revealed that pathogenic




Figure 2. TPM2 variants disrupt muscle development in Drosophila. (A) Transgenic expression assays used to characterize the effects of TPM2 variants on myogenesis. (B and C) TPM2 variants caused multiple phenotypes in *slou*-expressing muscles. (B) Diagram showing the 30 body wall muscles in an embryonic hemisegment; *slou.Gal4*-expressing muscles are shown in blue (modeled after ref. 7). Confocal micrographs of stage 16 embryos that expressed GFP-tagged Drosophila *Tropomyosin 2* (*Tm2*), wild-type human TPM2, or pathogenic TPM2 variants (green), colabeled with myosin heavy chain (MHC, violet). Two hemisegments are shown for each embryo. Variant-expressing LO1 muscles showed multiple phenotypes, including rounded muscles (elongation), muscles attached to an incorrect tendon (wrong tendon, white arrows), muscles attached to 3 tendons (multiple tendons, white arrowheads), muscles absent from a segment (missing), and muscles with bent or hook-shaped morphology (misshapen; yellow arrows). (C) Histogram of variant phenotypes. (D and E) TPM2 variants reduced muscle length in *nau*-expressing muscles. (D) The *nau.Gal4*-expressing muscles are diagrammed in blue. Confocal micrographs of stage 16 embryos that expressed GFP-tagged transgenes, labeled for GFP. Variant-expressing VO5 muscles were short or rounded, but other parameters of muscle morphology were largely normal. E122K expressing muscles showed the strongest phenotype (white arrows). GFP expression in VO4 muscles was highly variable. (E) Box plot showing VO5 length normalized to *Tm2*-expressing control. Significance versus *Tm2*-expressing muscles was determined by Fisher's exact test (C) or 1-way ANOVA (E). Error bars, standard error of the mean (SEM). * $(P < 0.05)$, ** $(P < 0.01)$, *** $(P < 0.001)$, **** $(P < 0.0001)$. $n \geq 66$ muscles per variant; minimum 9 embryos per variant. Scale bars, 20 μm .

TPM2 variants disrupt muscle development and muscle function. Transient overexpression proved to be a useful strategy for identifying *TPM2*-related disease mechanisms, so we used these assays to characterize 3 variants we identified in patients with musculoskeletal disorders. The variants V129A, E139K, and A155T caused phenotypes similar to those we identified for known pathogenic variants, providing additional evidence that the variants are in fact pathogenic. In addition, phenotypic consistency among our assays correlated with the severity of patient phenotypes, suggesting our disease models have the power to predict the clinical severity of *TPM2* variants. These studies identify defects in muscle development as a component for the etiology of *TPM2*-related disorders.

Results

We set out to model *TPM2*-related diseases in vivo by characterizing a panel of variants that represent the key characteristics of the spectrum of *TPM2* pathogenic variants. A set of 8 variants in highly conserved residues are causative of the 5 *TPM2*-associated disorders, including NM (K7Del, E41K, R133W), CM (K49Del, N202K), CFTD (E122K, R133P), DA (K7Del, E41K, R91G, R133W), and EVMPS (R133W; Table 1). The representative variants are also equally distributed between α -sheets (K7Del, K49Del, R91G, R133P/W) and β -sheets (E41K, E122K, N202K; Figure 1A). With respect to the *TPM2* coiled-coil heptad repeat, pathogenic variants generally cluster to *b*, *f*, and *g* residues (Figure 1B). The 8 representative variants clustered to the *f* (E41K, N202K) and *g* (K7Del, K49Del, R91G, E122K, R133P) positions, which is consistent with the overall distribution of pathogenic variants along the coiled-coil heptad (Figure 1B). The variants K7Del, E41K, K49Del, R91G, E122K, R133P, R133W, and N202K are thus a representative collection of *TPM2* mutations causative of congenital disease.

TPM2 variants disrupt myogenesis. Tropomyosin 2 (*Tm2*) is the *Drosophila* ortholog of *TPM2*, and the 2 proteins show a high degree of sequence conservation (Figure 1A). Overexpression studies in *Drosophila* have successfully modeled pathogenic variants in myosin heavy chain 3 (*MYH3*) associated with DA (37), so we used the binary UAS-GAL4 system to express GFP-tagged *Drosophila Tm2*, wild-type human *TPM2*, and the set of 8 *TPM2* variants in *Drosophila* embryonic muscle precursors. To minimize mRNA expression differences among the variants, UAS constructs were targeted to a common genomic landing site. The expression of endogenous *Tm2*, and the Gal4 drivers *slou.Gal4* and *nau.Gal4*, initiates immediately after muscle precursor specification (7, 8). In addition, *slou.Gal4* and *nau.Gal4* expression is spatially restricted to non-overlapping populations of muscle precursors (7). We used *slou.Gal4* and *nau.Gal4* to activate GFP-tagged transgenes in subpopulations of muscles and quantify muscle morphology at single-cell resolution (Figure 2A).

Embryonic muscles are named by their position and orientation in the segment, and the longitudinal oblique 1 (LO1) muscle shows a stereotypical oblique morphology (Figure 2B). LO1 muscles that expressed GFP-tagged *TPM2* variants under the control of *slou.Gal4* showed several abnormalities, including rounded and generally misshapen morphologies and attachments to the wrong tendon (Figure 2, B and C). Variant-expressing LO1 muscles also failed to develop in the correct position and were sometimes missing by the end of myogenesis (Figure 2, B and C). The frequency of LO1 muscle phenotypes was higher in muscles that expressed *TPM2* variants than in muscles that expressed wild-type *TPM2* or *Drosophila Tm2*, and LO1 muscles that expressed *K49Del* showed the highest frequency of muscle defects within the set of 8 pathogenic variants (Figure 2C). Ventral oblique 5 (VO5) muscles that expressed GFP-tagged pathogenic variants under the control of *nau.Gal4* were significantly shorter than VO5 muscles that expressed wild-type *TPM2* or *Tm2* (Figure 2, D and E). Among the variants tested, E122K caused the strongest phenotype in VO5 muscles (Figure 2E). Overall, our transgenic overexpression studies showed 7 of the 8 representative variants acted as gain-of-function mutations, demonstrating that pathogenic *TPM2* variants disrupt myogenesis in *Drosophila*.

Myogenesis is a multistep process that initiates with the specification of mononucleate muscle precursors known as myoblasts, which differentiate and fuse with each other to form multinucleate myotubes. Concurrent with myoblast fusion in *Drosophila*, nascent myotubes extend bilateral projections toward tendon cells at the segment border and identify correct muscle attachment sites through the process of myotube guidance. After attaching to tendon cells, myotubes assemble sarcomeres and mature into contractile myofibers (7). The phenotypes we identified in *TPM2*-expressing muscles occurred prior to sarcomere assembly, suggesting pathogenic *TPM2* variants could perturb myoblast fusion and myotube guidance prior to sarcomere assembly.




Figure 3. TPM2 variants disrupt myoblast fusion and myotube guidance. (A) Myoblast fusion assays. Confocal micrographs of stage 16 embryos that expressed cytoplasmic EGFP (green), nuclear RFP (violet), and wild-type or variant *TPM2* under the control of *slou.Gal4*. DT1 and LO1 muscles that expressed K49Del or E122K showed a substantial change in the number of myonuclei compared with controls. The number of myonuclei in other *slou*-expressing muscles was unaffected. (B) Quantification of myoblast fusion. Fusion index indicates altered myoblast fusion in variant-expressing myotubes. $n \geq 45$ myotubes per variant; minimum 8 embryos per variant. (C) Live imaging stills of LO1 myotubes in stage 12–15 embryos that expressed GFP-tagged *TPM2*. Transgene expression was controlled by *slou.Gal4*. Live imaging initiated when GFP fluorescence was first detected (0min). Dorsal leading edges (arrows) of control myotubes elongated to the dorsal anterior of the segment. Dorsal leading edges of variant-expressing myotubes failed to elongate or elongated toward the posterior of the segment. #:## (hr:min). (D) Quantification of myotube guidance. Control myotubes showed a stable myotube angle (consistent elongation toward a muscle attachment site) and a low roundness score (more linear). Variant-expressing myotubes showed fluctuating myotube angles and a high roundness score (more circular). (E) Hatching assays. *Tm2^{Δ8-261}* homozygous embryos had significantly lower hatching rates than controls (blue bars). *Tm2^{Δ8-261}* embryos that expressed human *TPM2* or Drosophila *Tm2* under the control of *Mef2.Gal4* showed significantly improved hatching rates compared with *Tm2^{Δ8-261}* embryos (red and violet bars). *Tm2^{Δ8-261}* embryos that expressed K49Del also showed a significant improvement in hatching rates (green and gray bars), but hatching rates were comparable between *Tm2^{Δ8-261}* embryos that expressed wild-type or K49Del variants. Significance was determined by 1-way ANOVA (B and E) or unpaired, 1-tailed Student's *t* test (D). Error bars, SEM. **($P < 0.01$), ***($P < 0.001$), ****($P < 0.0001$). Scale bars, 10 μm (A), 5 μm (C).

To test this hypothesis, we carried out in-depth myoblast fusion and myotube guidance assays on 2 variants that produced the strongest phenotypes in our transgenic overexpression studies, K49Del and E122K. Using the *slou.Gal4*-expressing dorsal transverse 1 (DT1) and LO1 muscles as a model, we found variant-expressing muscles had a significant reduction in myoblast fusion, except K49Del-expressing DT1 muscles, which showed enhanced fusion (Figure 3, A and B). Live imaging of LO1 myotube guidance showed the dorsal leading edge elongated to the dorsal anterior of the hemisegment, giving the LO1 muscle its characteristic oblique morphology (Figure 3, C and D, and Supplemental Video 1; supplemental material available online with this article; <https://doi.org/10.1172/jci.insight.152466DS1>). LO1 myotubes that expressed K49Del or E122K showed several unusual behaviors. Some K49Del-expressing myotubes would initiate elongation, but the leading edge would retract and show a rounded muscle phenotype at the end of myogenesis (Supplemental Video 1 and Figure 3, C and D). In other examples, the leading edge in K49Del-expressing myotubes would elongate appropriately, but the lateral membrane would form an ectopic leading edge and elongate to a third tendon cell (Supplemental Video 2 and Figure 3, C and D). In E122K-expressing myotubes, the dorsal leading edge would also elongate incorrectly toward the medial or posterior regions of the segment (Supplemental Video 3 and Figure 3, C and D). The studies suggest that the myogenic phenotypes in variant-expressing embryos are due to defects in myoblast fusion and myotube guidance.

TPM2 variants disrupt muscle function. In some cases, muscle weakness in patients with *TPM2*-associated myopathies is restricted to proximal muscles in infancy but then progresses to include distal muscles in adulthood (11). To model *TPM2* myopathies beyond embryonic development, we expressed Drosophila *Tm2* and human *TPM2* in the body wall muscles of larvae homozygous for the null allele *Tm2^{Δ8-261}*. Larvae develop through 3 distinct growth stages (L1–L3), which are characterized by extensive muscle hypertrophy (38). Muscle morphology was largely normal in *Tm2^{Δ8-261}* homozygous embryos, owing to a maternal contribution of *Tm2* (8), but only 58% of *Tm2^{Δ8-261}* embryos hatched into larvae (Figure 3E). Hatching assays have been used to associate defects in myoblast fusion, sarcomere function, and neurotransmitter release with reduced muscle performance (39–41). We found that *Tm2^{Δ8-261}* embryos that broadly expressed *Tm2* or *TPM2* in the musculature hatched at significantly higher rates than controls, suggesting muscle function was restored in *Tm2^{Δ8-261}* embryos (Figure 3E). Surprisingly, the hatching rate was not significantly different between *Tm2* and *TPM2* rescued embryos, between *Tm2* and *Tm2.K49Del* embryos, or between *TPM2* and *TPM2.K49Del* rescued embryos (Figure 3E). These data argue that *Tm2* and *TPM2* are functionally equivalent, at least in the context of hatching assays, and that wild-type and K49Del variants can substitute for *Tm2* in *Tm2*-null embryos. However, *Tm2^{Δ8-261}* rescued embryos did not develop beyond the L1 stage, independent of the transgene used for the rescue, suggesting endogenous *Tm2* is required outside of the musculature for viability or that the level of transgenic *Tm2* expression is functionally incompatible with endogenous expression levels.

To circumvent viability issues and model *TPM2* variants in late larval stages, we broadly expressed K49Del and E122K throughout the musculature of otherwise wild-type larvae and assayed muscle morphology and function. K49Del-expressing muscles were significantly longer in L3 larvae than controls, which could reflect a reduced contractile state (Figure 4, A and B). Standardized larval locomotion assays have been developed to assess muscle function (42), and L3 larvae that expressed K49Del showed a significant reduction in locomotor activity compared with *TPM2*-expressing controls (Figure 4C). Larvae that




Figure 4. TPM2 variants disrupt muscle function in Drosophila. (A–C) Larvae that expressed TPM2 variants showed abnormal muscle morphology and impaired muscle function. (A) Confocal micrographs of live L3 larvae that expressed GFP-tagged TPM2 or pathogenic TPM2 variants (green) under the control of *Mef2.Gal4*. Larvae that expressed pathogenic variants often lacked (arrowheads) or missing (arrow) muscles in segment A8. Muscles were also misshapen (arrowheads) or missing (arrow) in variant-expressing larvae. (B) Dorsal oblique muscle length (A2–A8). Muscles that expressed K49Del or R91G were significantly longer than controls. $n \geq 76$ muscles per genotype. (C) Larval locomotion assays. Larvae that expressed K49Del or R91G were significantly slower than controls. $n \geq 9$ larvae per genotype. Significance was determined by Kruskal-Wallis test. Error bars, SEM. *($P < 0.05$), **($P < 0.01$), ****($P < 0.0001$). Scale bars, 500 μm.

expressed E122K did not show significant changes in muscle size or locomotion (Figure 4, B and C). To model additional representative variants in larvae, we extended our functional studies to include E41K and R91G (Figure 2, C and E). Larvae that expressed R91G showed significantly longer muscles and reduced locomotor activity, whereas larvae that expressed E41K did not show significant changes in muscle size or locomotion (Figure 4, A–C). All 4 variants caused muscle loss (Figure 4A), arguing voluntary crawling performance in L3 larvae is resistant to changes in the number of myofibers. In summary, larvae that expressed K49Del or R91G showed significant reductions in muscle function, while larvae that expressed E41K or E122K trended toward reduced muscle function. Our developmental and functional studies of known pathogenic variants in the fly show that no single variant caused significant phenotypes in every assay, suggesting multiple assays will be needed to evaluate the pathogenicity and relative severity of TPM2 variants.




Figure 5. TPM2 variants disrupt myotube morphogenesis. (A) Transfection efficiency. C2C12 myoblasts were transfected with TPM2.IRES.GFP and imaged 24 hours posttransfection. About 25% of cells were GFP positive. (B) Western blot of TPM2 expression. C2C12 cells were transfected with Flag-TPM2 and collected after 3, 5, and 7 days of differentiation. (C) Western blot of TPM2 variants. C2C12 cells were transfected with Flag-tagged variants and collected after 7 days of differentiation. Protein expression was similar among the variants. (D) C2C12 cells transfected with pathogenic TPM2 variants showed impaired morphology. Confocal micrographs of cells fixed after 7 days in differentiation media and labeled for α -actinin (green) to detect differentiated myotubes and Hoechst to visualize myonuclei. Myotubes that expressed E41K, K49Del, R91G, and E122K appeared shorter than controls (wild-type TPM2

and the benign variant E273K). Variant-expressing myotubes were often rounded (arrows). Scale bars, 20 μm . (E) Myotube length distribution showing Gaussian distribution fit curves (solid lines). The length distribution of myotubes that expressed pathogenic variants skewed toward shorter lengths. (F) Quantification of myoblast fusion. Fusion index represents the number of nuclei in multinucleate myotubes; variant-expressing cells fused less than controls. (G) Roundness score. Individual myotubes were traced to calculate roundness; a score of 1.0 represents complete circularity. Myotubes that expressed K49Del and R91G were more round than controls. Significance was determined by unpaired, 1-tailed Student's *t* test (E) or 1-way ANOVA (F and G). $n \geq 10$ imaging fields per treatment. *($P < 0.05$), **($P < 0.01$), ***($P < 0.001$), ****($P < 0.0001$). Error bars, SEM.

TPM2 variants disrupt myotube morphogenesis in vitro. To further evaluate the impact of *TPM2* variants on myogenesis, we used C2C12 cells to model muscle development in a vertebrate system. C2C12 cells are immortalized mouse myoblasts that fuse under differentiation conditions to form multinucleate myotubes capable of extensive elongation (43). K7Del, E41K, K49Del, and E122K have been studied in C2C12 cells, and while the variant proteins failed to localize correctly, the phenotypes of the variant expressing myotubes were not characterized (9, 44). We found that *TPM2* expression constructs could be efficiently transfected in undifferentiated C2C12 myoblasts and that expression was maintained throughout differentiation (Figure 5, A and B, and uncut gels in the online supplemental material). In addition, endogenous *TPM2* mRNA was detectable in undifferentiated myoblasts, and expression increased 3.3-fold after 2 days of differentiation. We did not observe significant changes in the expression of wild-type or variant *TPM2* proteins in differentiated myotubes (Figure 5C). C2C12 cells are thus a feasible model for studying the effects of *TPM2* variants on muscle development.

Myotubes that expressed wild-type *TPM2* were morphologically similar to control treated cells after 7 days of differentiation (Figure 5D). E273K (rs3180843, LOVD variant 0000446934) is a benign variant that was identified in a patient with normal muscle function. Using E273K as a secondary control, we found myotubes that expressed E273K were indistinguishable from myotubes that expressed wild-type *TPM2* (Figure 5, D–G). In contrast, myotubes that expressed E41K, K49Del, R91G, and E122K showed significant reductions in myoblast fusion and myotube elongation compared with E273K-expressing cells (Figure 5, D–F). K49Del- and R91G-expressing myotubes were also more circular than controls (Figure 5G), arguing these variants disrupted elongation to a greater extent than E41K and E122K. Since C2C12 cells develop independently of other musculoskeletal tissues, our results argue *TPM2*-related disease mechanisms act cell autonomously on developing myofibers. These studies also show that E273K can be used as a benign benchmark to evaluate variants of uncertain significance.

TPM2 variants disrupt musculoskeletal system development in vivo. We recently modeled DA2A in zebrafish, and fish heterozygous for the knockin allele R672H in *MYH3* showed musculoskeletal abnormalities consistent with joint contractures (45). While the efficiency of genome-editing technologies in zebrafish is continuing to improve, the injection of variant-encoding capped mRNAs into fertilized embryos is a well-established tool for rapidly evaluating variant pathogenicity in developing embryos and larvae (46). Though this technique is difficult to use for large transcripts, we took advantage of the comparatively small *TPM2* coding sequence to generate and inject variant-encoding mRNAs into 1-cell stage embryos (Figure 6A). Similar to *Drosophila*, endogenous *TPM2* was detectable during myogenesis, and relative expression increased 3.9-fold from 12 to 24 hpf (Figure 6B). We injected a gradient of *TPM2* mRNA concentrations into 1-cell stage embryos and identified an optimized dose (600 pg) in which pathogenic variants produced musculoskeletal phenotypes while wild-type mRNAs did not (Figure 6, C and D). Protein from injected wild-type mRNA was strongly expressed 12–24 hpf and was nearly undetectable by 2 dpf (Figure 6E). However, clutch-to-clutch variation in protein expression at 24 hpf prevented us from assessing relative protein stability among the variants. Nonetheless, we successfully optimized mRNA injections and quantified musculoskeletal phenotypes to standardize and validate a transient overexpression assay in zebrafish.

Slow- and fast-twitch myofibers are spatially distinct in zebrafish; slow fibers are found just beneath the epidermis and are superficial to the fast fibers. At 26 hpf, larvae that expressed wild-type or E273K *TPM2* showed normal musculoskeletal features, whereas larvae that expressed E41K, K49Del, R91G, and E122K had significantly shorter slow fibers than controls (Figure 7, A and C). In addition, the slow fibers were disorganized, and the myofiber ends often clustered at the somite boundary or at the center of the somite (Figure 7A). Somite length at the level of slow fibers was shorter in larvae that expressed E41K, R91G, and E122K compared with E273K controls, and fewer slow fibers were present in larvae that expressed K49Del and R91G (Figure 7, C and D). Somite length at the level of fast fibers was significantly changed in larvae




Figure 6. Transient overexpression assays in zebrafish. (A) Transient expression assays were used to characterize myogenic defects in zebrafish that expressed *TPM2* variants. One cell stage embryos were injected with control or variant-encoding mRNAs and raised under standard conditions to 26 hours postfertilization (hpf) for histological assays or to 6 days postfertilization (dpf) for locomotor assays. (B) Quantitative real-time PCR of zebrafish *TPM2* in wild-type embryos, normalized to 12 hpf. $n = 4$ larvae per sample; 3–4 replicates are shown. (C) Histologic measurements of 26 hpf larvae. Individual slow muscle fibers were traced in ImageJ (NIH) to determine muscle length (magenta line). Somite size was measured 3 times per somite and then averaged to calculate somite length. (D) Pathogenic *TPM2* variants caused dose-dependent defects in myofiber length and somite length. A gradient of mRNA doses were injected (200 pg, 400 pg, and 600 pg), and muscle morphology was assessed at each concentration. A dose of 600 pg produced consistent phenotypes in variant-expressing larvae but not in wild-type expressing larvae. Each data point represents an individual muscle fiber or somite. $n \geq 20$ larvae per condition. (E) Western blot of injected TPM2. One-cell stage embryos were injected with 600 pg Flag-TPM2 mRNA, and lysates were collected at 12 hpf, 24 hpf, 2 dpf, 3 dpf, and 5 dpf. Robust TPM2 expression was detectable at 12 hpf and 24 hpf. Each data point graphed represents relative expression from 1 independent clutch. $n \geq 30$ animals per sample; 4 replicates are shown. Significance was determined by unpaired, 1-tailed Student's *t* test versus wild-type *TPM2*-injected fish. **($P < 0.01$), ***($P < 0.001$), ****($P < 0.0001$). Error bars, SEM.




Figure 7. Pathogenic *TPM2* variants disrupt myogenesis in zebrafish. (A) Larvae that expressed pathogenic variants showed defects in muscle morphogenesis. Confocal micrographs of slow-twitch myofibers (left, F-actin) and fast-twitch myofibers (right, myosin light chain) in 26 hpf larvae injected at the 1-cell stage. Variant-expressing larvae showed multiple slow fiber phenotypes, including short fibers (red arrows) and fibers that clustered to a single attachment site (yellow arrowheads). Fast-twitch fiber morphology was largely normal in larvae that expressed pathogenic variants, although some larvae showed disorganized fast fibers (blue arrows). Larvae that expressed wild-type *TPM2* or the benign variant E273K had morphologically normal slow and fast fibers. (B) Larvae that expressed pathogenic variants showed defects in myosepta morphology. Confocal micrographs of 26 hpf larvae injected at the 1-cell stage, labeled for slow myofiber myosin heavy chain (MyHC, green) and the myosepta tendon marker Thrombospondin 4 (THBS4, violet). Variant-expressing larvae showed multiple phenotypes, including tendons that developed in the center of the somite (red arrowhead), bifurcated myosepta (orange arrowheads), and myosepta with broken thrombospondin expression (yellow arrowheads). The frequency of tendon phenotypes was substantial only for E122K. (C) Gaussian distribution fit curves. Length distributions in larvae that expressed pathogenic variants skewed toward shorter lengths for slow fibers but were less affected for fast fibers. $n \geq 48$ somites per treatment. (D) Box plots showing slow fiber number and the frequency of morphology defects in fast muscle and myosepta. Larvae that expressed K49Del and R91G had significantly fewer slow fibers than larvae that expressed E273K. Morphology defects were restricted to E41K-expressing larvae (fast fibers) and E122K-expressing larvae (myosepta). $n \geq 11$ larvae per treatment. Scale bars, 20 μm . Significance was determined by unpaired, 1-tailed Student's *t* test (C) and 1-way ANOVA (D). * ($P < 0.05$), ** ($P < 0.01$), *** ($P < 0.001$), **** ($P < 0.0001$). Error bars, SEM.

that expressed E41K and E122K compared with E273K controls, and although fast fiber morphology was difficult to visualize at the single-cell level, larvae that expressed E41K showed defects in fast fiber organization (Figure 7, C and D).

Myofibers in the trunk attach to tendons in the myosepta, which are located along the somite boundaries and strongly express the tendon structural protein THBS4 (Figure 7B). Larvae that expressed wild-type or E273K showed a normal tendon pattern, whereas larvae that expressed K49Del and E122K showed multiple tendon phenotypes that included tendons incorrectly positioned in the center of the somite, bifurcated myosepta, and myosepta with broken or incomplete expression of thrombospondin (Figure 7, B and D). These *in vivo* studies provide further evidence that pathogenic *TPM2* variants disrupt musculoskeletal system development. In addition, the musculoskeletal phenotypes in our transient overexpression assay can faithfully distinguish benign *TPM2* variants from pathogenic variants.

TPM2 variants disrupt muscle performance *in vivo*. The startle response in zebrafish larvae is a well-characterized reflex used to assay motor function, and we previously showed muscle function is compromised in a *MYH3* model of DA using the larval startle response (45). To understand if *TPM2* variants affect muscle function in zebrafish, we injected mRNAs into 1-cell stage embryos and ran automated tracking assays in larvae at 6 dpf (Figure 6A and Figure 8A). After a stimulus, the startle response induces a reflexive swim behavior that is quantified by distance swum, average escape velocity, and maximum velocity. Although transient overexpression of *TPM2* variant mRNAs did not induce protein expression beyond 2 dpf (Figure 6E), we hypothesized that the developmental defects we observed in variant-expressing larvae would affect swim function at 6 dpf. Surprisingly, larvae that expressed pathogenic variants did not show significant changes in swim function compared to E273K-expressing larvae, although K49Del- and R91G-expressing animals trended toward reduced swim distance and escape velocity (Figure 8, B–D). One explanation for normal swim function in variant-expressing larvae is that muscle development continues beyond transient overexpression, which ends at 2 dpf. It is possible that newly developed and presumably wild-type muscle partially compensates for the developmental defects we identified at 26 hpf.

TPM2 variants are identified in patients with musculoskeletal disorders. As part of our ongoing clinical sequencing of patients with musculoskeletal disorders, we identified 2 potentially novel *TPM2* variants and 1 recurring variant. Patient I presented with isolated bilateral clubfoot but no hand contractures and was found to be heterozygous for V129A (Figure 9A). Patients II and III are unrelated patients who were diagnosed with DA1, and were found to be heterozygous for E139K and A155T, respectively (Figure 9, B and C). Patient III also had mild distal lower extremity weakness and fatigue upon running. All 3 patients showed symptoms at birth, but none required interventions for motility or respiration (Table 2). There was no family history of arthrogyrosis or clubfoot for any of the 3 patients, but parents and other family members were unavailable for genotyping. Two of the *TPM2* variants, V129A and E139K, had not previously been identified in patients with myopathies or arthrogyroses, although CM has been linked to the variant E139Del (12, 47). The third variant, A155T, was previously identified in a Chinese family with DA1 (48).

Variants disrupt myotube morphogenesis in vitro. To evaluate the pathogenicity of V129A and E139K, and to characterize the severity of A155T relative to other variants, we assayed the impact of each variant on C2C12 cell morphology. Similar to other *TPM2* variants, there was no difference in the expression of V129A, E139K, and A155T proteins in differentiated myotubes compared to controls (Figure 9D).




Figure 8. TPM2 variants did not affect swim function. (A) Automated tracking of the startle response in 6 dpf larvae. EthoVision imaging software (Noldus) tracked larvae for 3 seconds after a mechanical stimulus. Red lines show the locomotor path of representative larvae. Endpoints are marked by a square. (B–D) Box plots showing swim function. The startle response in larvae that expressed E41K, K49Del, R91G, and E122K was not significantly different from larvae that expressed the benign variant E273K. Swim distance, average escape velocity, and maximum velocity of larvae that expressed TPM2 variants were reported by imaging software and normalized to larvae that expressed wild-type TPM2. Significance was determined by 1-way ANOVA. $n \geq 25$ larvae per treatment. Error bars, SEM.

Myotubes that expressed V129A, E139K, and A155T showed reduced myotube elongation compared with E273K-expressing cells (Figure 9, E and F), and myotubes that expressed A155T showed reduced myoblast fusion (Figure 9G). E139K- and A155T-expressing myotubes were also more circular than controls (Figure 9H), arguing these variants disrupted elongation to a greater extent than V129A. Thus, myotubes that expressed V129A, E139K, and A155T showed more significant phenotypes than the benign variant E273K, which provides additional evidence that V129A, E139K, and A155T are pathogenic.

TPM2 variants disrupt muscle development and function in zebrafish. The residues affected by V129A, E139K, and A155T are conserved in zebrafish (Figure 1A), so we used our transient overexpression assay to further characterize the effect of each variant on musculoskeletal system development in vivo. Larvae that expressed V129A, E139K, and A155T showed defects in musculoskeletal morphogenesis similar to those that expressed known pathogenic variants (Figure 8, A and B). Slow fibers from larvae that expressed V129A and A155T were significantly shorter than in E273K-expressing controls (Figure 10, A and C). Variant-expressing slow fibers were also disorganized and often clustered to the center of the somite (Figure 10A). Somite length at the level of slow fibers was shorter in larvae that expressed A155T and longer in larvae that expressed E139K (Figure 10C). Fewer slow fibers were present in larvae that expressed A155T (Figure 10D). Somite length at the level of fast fibers was significantly changed in larvae that expressed V129A and A155T compared with E273K controls, but fast fiber morphology was unaffected (Figure 10, C and D). In addition, larvae that expressed V129A, E139K, and A155T showed a significant increase in the frequency of tendon phenotypes compared with E273K controls (Figure 10D).

We performed startle response assays on larvae that expressed V129A, E139K, and A155T and found A155T-expressing larvae showed significantly reduced swim distance, average escape velocity, and maximum velocity compared with E273K-expressing larvae (Figure 10E). V129A-expressing larvae trended toward reduced swim performance but were not significantly different from controls (Figure 10E). The TPM2 variants we identified in patients with musculoskeletal disorders caused defects in musculoskeletal system development. In the case of A155T, functional defects persisted for 4 days longer than protein expression, suggesting the developmental phenotypes in larvae that expressed A155T were more severe than in larvae expressing any other variant. Our assays in C2C12 cells and zebrafish provided additional evidence that the potentially novel TPM2 variants V129A and E139K are pathogenic, and the results argue that A155T is causative of TPM2-related musculoskeletal disorders.




Figure 9. TPM2 variants identified in patients with musculoskeletal disorders disrupt myotube morphogenesis. (A) Clinical features of patient I, diagnosed with bilateral clubfoot (shown here before treatment). (B and C) Clinical features of patient II and patient III, diagnosed with DA1. Photos for patient II show clubfoot before treatment, and photos of patient III show bilateral clubfoot after treatment. Individual III also developed lower extremity weakness as a child. Patient I and patient II are heterozygous for the novel variants V129A and E139K; patient III is heterozygous for the recurring variant A155T. (D) Western blot of TPM2 variants. C2C12 cells were transfected with Flag-tagged variants and collected after 7 days of differentiation. Protein expression was similar among V129A, E139K, and A155T. (E) C2C12 cells transfected with pathogenic TPM2 variants showed defective morphology. Confocal micrographs of cells fixed after 7 days in differentiation media and labeled for α -actinin (green) to detect differentiated myotubes and Hoechst to visualize myonuclei. Myotubes that expressed V129A, E139K, and A155T appeared shorter than controls expressing

the benign variant E273K. Variant-expressing myotubes were often rounded (arrows). Scale bars, 20 μm . (F) Myotube length distribution showing Gaussian distribution fit curves (solid lines). The length distribution of myotubes that expressed V129A, E139K, and A155T skewed toward shorter lengths. (G) Quantification of myoblast fusion. Fusion index represents the number of nuclei in multinucleate myotubes; cells that expressed A155T fused less than controls. (H) Roundness score. Individual myotubes were traced to calculate roundness; a score of 1.0 represents complete circularity. Myotubes that expressed E139K and A155T were more round than controls. Significance was determined by unpaired, 1-tailed Student's *t* test (E) or 1-way ANOVA (F and G). $n \geq 10$ imaging fields per treatment. ****($P < 0.0001$). Error bars, SEM.

Discussion

To date, over 30 *TPM2* variants have been identified in patients with myopathies and arthrogryposes, but the biochemical properties of only a few variants have been tested. Furthermore, *in vivo* studies investigating the physiological consequences of pathogenic *TPM2* variants were largely lacking. We expressed *TPM2* variants in multiple model systems and found pathogenic variants disrupted muscle development and muscle function. By focusing on 4 pathogenic variants, we developed a transient overexpression assay in zebrafish that benchmarked musculoskeletal phenotypes of pathogenic variants against a known benign variant. Clinical sequencing of patients with structural birth defects identified 2 potentially novel *TPM2* variants, V129A and E139K, and a recurring variant, A155T, which we tested with our transient overexpression assay. V129A, E139K, and A155T caused musculoskeletal defects similar to those of the known pathogenic variants, and our analyses provide support for pathogenicity of all 3 variants. A155T produced the most consistent phenotypes of the variants we tested, and the clinical symptoms of the patient with the A155T variant were the most severe among the patients in our study. Our results argue that one pathomechanism of *TPM2*-related disorders is disrupted muscle development and that transient overexpression assays can efficiently characterize variants of uncertain significance identified in patients with musculoskeletal disorders.

Investigations of *TPM2*-related disease mechanisms have largely focused on understanding the role of *TPM2* in the sarcomere. Thin filament motility assays have uncovered the biochemical properties of *TPM2* variants in response to Ca^{2+} , and the pathogenic variants tested so far have shown both increased and reduced Ca^{2+} sensitivity (Table 1). The basis for Ca^{2+} sensitivity is thought to reside in the flexibility or rigidity of the *TPM2* dimer, which correlates with the ability of troponin and myosin to shift tropomyosin away from actin (27–31). Here, we found that *TPM2* variants disrupted muscle morphogenesis prior to sarcomere assembly *in vivo*. Our live imaging in *Drosophila* embryos showed myotubes that expressed K49Del and E122K had elongation defects and used inappropriate muscle attachment sites to adhere to the exoskeleton (Supplemental Videos 1–3). We observed similar myotube elongation defects in C2C12 cells that expressed pathogenic *TPM2* variants. Since C2C12 cells develop in the absence of positional cues from other tissues, our studies argue *TPM2* disease mechanisms act cell autonomously to disrupt myofiber morphogenesis prior to sarcomere assembly.

Tropomyosin has well-documented roles outside of the sarcomere in nonmuscle cells, most notably during cell migration. Dynamic changes to the cytoskeleton, coupled with changes in the expression of cell adhesion proteins, drive cell migration. Tropomyosins regulate the rate of actin polymerization and depolymerization (5, 49, 50), so it is not surprising that *TPM2* and *TPM3* are required for single-cell as well as collective cell migration (3, 4). In vertebrates, myoblasts specified in somites migrate to sites of muscle morphogenesis, where they fuse to form myotubes that in turn elongate and attach to tenocytes (51, 52). During zebrafish myogenesis, myoblasts that give rise to slow- and fast-twitch myofibers are developmentally distinct. Slow myoblasts known as adaxial cells are specified medially, nearest the notochord, and migrate radially to form elongated myotubes on the superficial, outermost region of the somite (53). The slow-twitch region of the myotome in larvae that expressed pathogenic *TPM2* variants (Figure 7A and Figure 10A) bore a striking resemblance to the slow-twitch myotome of larvae with defective adaxial cell migration (54). It is possible that pathogenic *TPM2* variants disrupt myoblast cell migration in zebrafish, suggesting myoblast migration may be affected in patients with *TPM2*-related disorders.

Drosophila embryonic myoblasts do not migrate because muscles are specified at the site of myogenesis. However, similar to vertebrates, *Drosophila* myoblasts fuse to form myotubes, and all the *TPM2* variants we tested disrupted myoblast fusion (Figure 3, A and B, Figure 5F, and Figure 9G). Myotubes also elongate and identify muscle attachment sites (7). Myotube elongation and attachment site selection are collectively known as myotube guidance, which is similar to axon guidance in many respects. Myoblast fusion and myotube guidance depend on regulated changes to the actin cytoskeleton (7, 8, 55). The *TPM2*

Table 2. Clinical phenotypes associated with *TPM2* variants

	E41K	K49Del	R91G	E122K	V129A	E139K	A155T, A155V
Diagnosis	NM, CM	CM	DA1	Unspecified myopathy	Isolated bilateral clubfoot	DA1	DA1, CM
Age at onset	Birth	8 y	Birth	4 mo	Birth	Birth	Birth
Proximal and distal muscle weakness	+	+	-	+	-	-	+
Facial muscle weakness	+	-	-	+	-	-	-
Respiratory insufficiency	+	+	-	-	-	-	+
Joint contractures	-	-	+	-	+	+	+
Motor or respiratory interventions	R	M	-	M	-	-	R
<i>Drosophila</i> phenotype ^A	0.6	1.6	3.3	1.0	nd	nd	nd
Myotube phenotype ^B	1.6	3.3	3.3	2.0	1.3	2.6	4.0
Zebrafish phenotype ^B	1.6	0.3	1.6	3.3	1.6	1.3	2.6
Reference	11	13	16	21	This study	This study	This study, 48, 57

Clinical data summarize reports for a single patient, except E41K and A155T/V, which reflect 2 patients. ^APhenotypic score: 0 (NS), 1 ($P < 0.05$), 2 ($P < 0.01$), 3 ($P < 0.001$), 4 ($P < 0.0001$); average reported for assays shown in Figure 2, C and E; and Figure 4, B and C. ^BPhenotypic score: average reported from radar plots shown in Figure 11A. CM, cap myopathy; DA1, distal arthrogryposis, type 1; M, mobility intervention of wheelchair for long distances; nd, not done; NM, nemaline myopathy; R, nightly respiratory intervention.

muscle morphogenesis defects we characterized in *Drosophila*, zebrafish, and cultured cells are likely the result of improperly regulated actin dynamics during myoblast migration, myoblast fusion, and myotube elongation. DA and amyoplasia (absence of muscle) were often thought to be distinct clinical diagnoses, but amyoplasia was recently reported in a case of congenital DA (56). Our studies provide additional support for a model in which *TPM2* variants disrupt muscle development.

At present, 14 *TPM2* variants have been identified in patients with myopathies and arthrogryposes in which the significance of the variant has not been definitively defined (Table 3). The number of *TPM2* variants with uncertain significance is likely to increase because these variants are being identified in patients with isolated clubfoot, which is much more common than myopathies or arthrogryposes. The incidence of clubfoot in the United States is 1:1000 live births, but the underlying causes are often unknown. One approach toward understanding isolated clubfoot is to expand clinical sequencing, which will likely uncover novel *TPM2* variants. Phenotypic variability among patients with *TPM2* variants can make genotype-phenotype correlations difficult (19), but the stringency of our benchmarked assays unambiguously defined variants as pathogenic or benign.

Transient overexpression in zebrafish has several advantages over the assays we developed. First, variant mRNAs can be generated from any vector with a T3, T7, or Sp6 promoter without requiring specialized expression or transgenic vectors. Second, mRNA injections into 1-cell stage embryos are fast, and the assays are generally complete and analyzed statistically within 2–3 days. Several weeks of breeding are required to identify and characterize stable transgenes in *Drosophila*, and C2C12 cell assays require 7 days of differentiation after transfection. In addition to speed and convenience, zebrafish carry out all stages of myogenesis and generate a musculoskeletal system with an endoskeleton. Zebrafish are therefore more similar to patients than our other models. Considering the advantages of zebrafish as a system, our transient overexpression assay could be further used to uncover new pathogenic variants of *TPM2* and to test additional genes of uncertain significance that contribute to the pathology of isolated clubfoot or other musculoskeletal disorders.

A155T caused the most consistent and significant phenotypes of the variants we tested (Figure 11A), and patients with the A155T variant experienced a wider range of clinical symptoms than patients with other variants (Table 2). Patient III from this study was diagnosed with DA1 due to joint contractures but also showed proximal and distal muscle weakness. Five members of a family carrying the A155T variant were also diagnosed with DA1 due to ulnar bilateral joint contractures (48). An unrelated patient heterozygous for A155V presented with respiratory insufficiency that required multiple interventions, along with extreme muscle weakness in the limbs. Upon muscle biopsy, the patient was diagnosed with CM (57). Patients with A155 variants have therefore shown symptoms associated with both myopathies and arthrogryposes.




Figure 10. *TPM2* variants disrupt myogenesis and muscle function. (A) Larvae that expressed V129A, E139K, and A155T showed defects in muscle morphogenesis. Confocal micrographs of slow-twitch myofibers (left, F-actin) and fast-twitch myofibers (right, myosin light chain) in 26 hpf larvae injected at the 1-cell stage. Variant-expressing larvae had phenotypes including short slow fibers (red arrows) that often clustered at the center of the somite and disorganized fast fibers (blue arrows). Larvae that expressed wild-type *TPM2* or the benign variant E273K had morphologically normal myofibers. (B) Larvae that expressed V129A, E139K, and A155T showed defects in myosepta morphology. Confocal micrographs of 26 hpf larvae injected with *TPM2* RNAs at the 1-cell stage, labeled for slow myofiber myosin heavy chain (MyHC, green) and the myosepta tendon marker Thrombospondin 4 (THBS4, violet). Larvae that expressed pathogenic variants developed tendons in the center of the somite (red arrowhead) and showed broken thrombospondin expression (yellow arrowheads). (C) Gaussian distribution fit curves. Slow fiber length distributions in larvae that expressed V129A and A155T skewed toward shorter lengths. Somite size was smaller in larvae that expressed A155T and longer in larvae that expressed E139K. $n \geq 48$ somites per treatment. (D) Box plots quantifying myofiber number and morphology defects. Larvae that expressed A155T had significantly fewer slow fibers than larvae that expressed E273K. Morphology defects were restricted to myosepta in larvae that expressed V129A, E139K, and A155T. $n \geq 7$ larvae per treatment. (E) Automated tracking of the startle response in 6 dpf larvae, as described in Figure 8. Larvae that expressed A155T had reduced startle responses compared with E273K larvae. $n \geq 24$ larvae per treatment. Swim parameters were normalized to larvae that expressed wild-type *TPM2*. Significance was determined by unpaired, 1-tailed Student's *t* test (C) and 1-way ANOVA (D and E). * ($P < 0.05$), ** ($P < 0.01$), *** ($P < 0.001$), **** ($P < 0.0001$). Error bars, SEM.

In contrast, patients carrying the other variants we tested showed either myopathy-related muscle weakness (E41K, K49Del, E122K) or arthrogryposis-related contractures (R91G, V129A, E139K), but not both (Table 2). These results highlight the exciting possibility that our myogenesis and muscle function assays can predict the clinical severity of *TPM2* variants.

Mechanistically, the A155 residue is predicted to mediate intermolecular hydrophobic interactions that shape and stabilize the *TPM2* dimer, and A155T is the only variant we tested that changes a residue involved in hydrophobic interactions within the Tropomyosin coiled-coil (Figure 11, B and C). K49Del and R91G affect residues involved in charged intermolecular interactions, and E41K, E122K, V129A, and E139K affect residues that likely mediate interactions between *TPM2* and other thin filament proteins (Figure 11B). However, phenotypic severity in myogenic assays did not further subdivide between charged and protein-protein interactions. These observations suggest residues that mediate hydrophobic interactions are the most critical for *TPM2* function during myogenesis, which is further supported by the fact that of the 25 known pathogenic variants, only A155T/V and Q218Del affect residues at sites of hydrophobic interactions. Of the 14 variants of uncertain significance in *TPM2* that remain to be characterized, only Q276E is predicted to disrupt hydrophobic interactions. We hypothesize that variants affecting hydrophobic interactions are the least tolerated and therefore appear less in the patient population. This hypothesis predicts that Q276E will produce consistent and significant phenotypes in our myogenic assays.

Methods

Drosophila genetics

The *TPM2* and *Tm2* transgenic variants were constructed by PCR cloning the *TPM2* ORF (clone HsCD00368588, PlasmID) and the *Tm2* ORF (RE15528, Berkeley *Drosophila* Genome Project) into pEntr (Life Technologies), followed by recombination into destination vector TWG (Drosophila Genome Resource Center) to add a C-terminus GFP tag. TWG clones served as a template to generate variants by site-directed mutagenesis as described before (58). Tagged and untagged ORFs were PCR subcloned into pUAS.attB using EcoRI/XbaI. All constructs were targeted to the same attP site on chromosome 3L (65B2) using Φ C31 integrase and standard injection methods (Rainbow Transgenic Flies, Inc.). pUAS.attB constructs were fully sequenced prior to injection.

Cell culture

TPM2 mammalian expression constructs were generated by PCR subcloning variants from pUAS.attB into pCMV-IRES-eGFP (Addgene 78264) using XbaI/EcoRI. C2C12 cells (obtained from ATCC) were seeded in 6-well plates, grown in standard conditions to 60% confluence in growth medium (10% FBS in DMEM), and transfected with 1.5 μ g of DNA per manufacturer's specifications (Lipofectamine 3000, L3000015, Thermo Fisher Scientific). Empty pCMV-IRES-eGFP was used as a control. Growth media were changed to differentiation media (2% horse serum in DMEM) 24 hours after transfection; cells were differentiated for 7 days prior to fixation.

Table 3. TPM2 variants of uncertain significance

Variant	Clinical significance ^A	Condition	Residue (helical wheel)
D2V	Likely pathogenic	Not provided	b
Q9P	Likely pathogenic	Inborn genetic disease	b
S61P	Likely pathogenic	NM4	e
K77R	Conflicting interpretations	DA1A	g
R90H ^B	Likely pathogenic	NM	f
Q93H	Likely pathogenic	Not provided	b
Q103K	Likely pathogenic	DA2B	e
E115Del	Uncertain	DA1A	c
K128E	Uncertain	DA1A	b
H153Q	Uncertain	DA1A	f
R178L	Uncertain	DA1A	c
D212G	Uncertain	DA1A	b
L227V	Uncertain	DA1A	c
Q276E	Uncertain	DA1A, DA2B, NM	d

^AReported in ClinVar. ^BAll variants showed germline inheritance except R90H (maternal inheritance). DA1A, distal arthrogyrosis, type 1a; DA2B, distal arthrogyrosis, type 2b; NM, nemaline myopathy.

Fish genetics and injections

Wild-type zebrafish were from line AB (obtained from the Washington University School of Medicine Zebrafish Consortium). *TPM2* variants were PCR subcloned from pUAS.attB into pCR2.1 (K202040, Thermo Fisher Scientific), capped RNAs were transcribed with a T7 mMessage mMachine kit (AM1344, Thermo Fisher Scientific), and embryos from natural spawning were injected with up to 600 pg RNA in phenol red (P0290, MilliporeSigma, 1:6). Injected embryos were maintained at 28.5°C in egg water and collected at 26 hours for histology or at 6 dpf for functional assays (feeding protocols began at 4 dpf). Multiple clutches were injected and pooled for each variant tested unless otherwise noted. Control injected larvae were collected to normalize each cohort.

Immunohistochemistry, imaging, and image quantification

Drosophila. Dechorionated embryos were fixed in 4% formaldehyde, devitellinated with heptane/methanol, and antibody stained as described before (58). Antibodies used were α -Mef2 (1:1000, gift from R. Cripps, San Diego State University, San Diego, California, USA; generated as described in ref. 59), α -myosin heavy chain (1:600, Abcam, catalog MAC147), α -GFP (1:600, Torrey Pines Biolabs, catalog TP-401), and α - β gal (1:100, Promega, catalog Z3781). HRP-conjugated secondary antibodies (goat anti-mouse Fluor 488 catalog 115-545-166, goat anti-rabbit Fluor 488 catalog 111-545-003, and goat anti-rat Fluor 594 catalog 112-585-167, all Jackson ImmunoResearch) in conjunction with the TSA system (Molecular Probes) were used to detect primary antibodies.

C2C12 cells. Differentiated cells were fixed for 15 minutes in 4% paraformaldehyde (PFA), blocked in 5% NGS/PBS, and incubated overnight with α -alpha-actinin (catalog A7811, MilliporeSigma, 1:1000). Primary antibodies were visualized with an Alexa Fluor 594-conjugated secondary antibody (catalog 115-585-003, Jackson ImmunoResearch Laboratories); myonuclei were visualized with Hoechst (H3570, Thermo Fisher Scientific, 1:1000).

Zebrafish. Hand-dechorionated larvae were fixed in 4% PFA for 1 hour and directly stained with Alexa Fluor 555-conjugated phalloidin (catalog A34055, Thermo Fisher Scientific, 1:200) for 2 hours at room temperature or blocked in 5% NGS/PBS-Triton-X 0.1% for 1 hour and incubated overnight with primary antibodies: THBS4 (Abcam, catalog ab211143, 1:100), myosin heavy chain (clone F59, Developmental Studies Hybridoma Bank, 1:50), and myosin light chain (clone F310, Developmental Studies Hybridoma Bank, 1:50). HRP-conjugated secondary antibodies in conjunction with the TSA system were used to detect primary antibodies.

Imaging. Embryos and larvae were imaged with a Zeiss LSM800 confocal microscope; cells were imaged with an inverted Zeiss Axio Observer. *Drosophila* larvae were live-imaged in PBS-Tween 20 after 5-minute exposure to diethyl ether. For time-lapse imaging, dechorionated Stage 12 *Drosophila*

Locomotion and startle response assays, hatching assays, Western blotting, quantitative real-time PCR, and protein modeling

See Supplemental Data 1.

Clinical sequencing

All patients were recruited from St. Louis Children's Hospital or Shriners Hospital St. Louis. The institutional review board approved this study and all patients and/or parents provided informed consent. Exome sequencing was performed as described before (60) on a cohort of patients with isolated clubfoot and distal arthrogryposis. Variants were validated by Sanger sequencing.

Statistics

Statistical analyses were performed with GraphPad Prism 9 software, and significance was determined with the unpaired, 1-tailed Student's *t* test; 1-way ANOVA; or nonparametric tests (for non-Gaussian distributions). Gaussian distribution fit curves were generated with Origin 2019 software. The box plots depict the 5th to 95th percentiles (whiskers), the upper and lower quartiles (boxes), and the median. Sample sizes are indicated in the figure legends, and *P* values less than 0.05 were considered significant. Data collection and data analyses were routinely performed by different authors to prevent potential bias. All individuals were included in data analysis.

Drosophila. Muscle morphology and size were visualized by Tropomyosin-conjugated GFP in hemisegments A2–A8, using 6–10 Stage 16 embryos per genotype. For morphology, muscles were assigned a phenotype (normal, missing, misshapen, elongation defect, attachment site defect), reported as a frequency. Myoblast fusion was quantified by counting the number of lacZ⁺ myonuclei per hemisegment (A2–A8) in *rP298.nlacZ* embryos. Fusion index = (#lacZ nuclei experimental/#lacZ nuclei control) × 100.

Zebrafish. Methods for measuring musculoskeletal parameters are shown in Figure 5 and largely reflect those reported previously (61). To control for day-to-day variability in embryo injections, muscle measurements were first normalized to the daily control and then reported as a percentage of control.

C2C12 cells. Absolute myotube length was used for comparisons among treatment groups. Fusion index = (#nuclei in multinucleate myotubes/total nuclei) × 100. A minimum of 10 fields were quantified per treatment for each parameter.

Study approval

Danio rerio were maintained in accordance with approved institutional protocols under the supervision of the Institutional Animal Care and Use Committee of Washington University, which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. *Drosophila* work did not require committee oversight. Patient studies were performed under the approval of the Institutional Review Board of Washington University. Written informed consent was obtained from all participants or their guardians. Written informed consent was also provided for photos appearing in the manuscript.

Author contributions

ANJ, CAG, MJG, JM, and SY conceived the study; ANJ, CAG, and SY developed methodology; SY, JM, GH, CAG, MJG, TO, MBD, and ANJ performed formal analysis; SY, JM, GH, and ANJ investigated; CAG and ANJ provided resources; SY, JM, and ANJ curated data; ANJ, CAG, and MJG wrote the original draft; SY and ANJ visualized data; SY, JM, and ANJ supervised the study; ANJ performed project administration; CAG, MJG, and ANJ acquired funding.

Acknowledgments

We thank the Washington University School of Medicine Zebrafish Consortium for providing an outstanding environment to conduct fish work. ANJ was supported by NIH R01AR070299 (National Institute of Arthritis and Musculoskeletal and Skin Diseases), and ANJ and CAG were supported by NIH R03HD104065 (*Eunice Kennedy Shriver* National Institute of Child Health and Human Development, NICHD). MJG is supported by NIH R01HL141086 and the Children's Discovery Institute of Washington University and St. Louis Children's Hospital PM-LI-2019-829. Research reported in this publication was

also funded by the *Eunice Kennedy Shriver* NICHD of the NIH under Award number 3P50HD103525-01S1 to the Intellectual and Developmental Disabilities Research Center at Washington University, the Washington University Institute of Clinical and Translational Sciences Award number UL1TR002345 from National Center for Advancing Translational Sciences; and R01AR067715-06 (to CAG and MBD).

Address correspondence to: Aaron Johnson, Department of Developmental Biology, 4523 Clayton Road, CB8103, St. Louis, Missouri 63108, USA. Phone: 314.273.1834; Email: anjohnson@wustl.edu.

GH's present address is: Graduate program in genetics and genomics, Baylor College of Medicine, Houston, Texas, USA.

1. Hardeman EC, et al. Impact of the actin cytoskeleton on cell development and function mediated via tropomyosin isoforms. *Semin Cell Dev Biol.* 2020;102:122–131.
2. Squire JM, et al. Myosin and actin filaments in muscle: structures and interactions. *Subcell Biochem.* 2017;82:319–371.
3. Shin H, et al. Tropomyosin isoform Tpm2.1 regulates collective and amoeboid cell migration and cell aggregation in breast epithelial cells. *Oncotarget.* 2017;8(56):95192–95205.
4. Lees JG, et al. Tropomyosin regulates cell migration during skin wound healing. *J Invest Dermatol.* 2013;133(5):1330–1339.
5. Bugyi B, et al. How tropomyosin regulates lamellipodial actin-based motility: a combined biochemical and reconstituted motility approach. *EMBO J.* 2010;29(1):14–26.
6. Wang W, et al. P2Y6 regulates cytoskeleton reorganization and cell migration of C2C12 myoblasts via ROCK pathway. *J Cell Biochem.* 2018;119(2):1889–1898.
7. Yang S, et al. FGF signaling directs myotube guidance by regulating Rac activity. *Development.* 2020;147(3):dev183624.
8. Williams J, et al. Noncanonical roles for Tropomyosin during myogenesis. *Development.* 2015;142(19):3440–3452.
9. Mokbel N, et al. K7del is a common TPM2 gene mutation associated with nemaline myopathy and raised myofibre calcium sensitivity. *Brain.* 2013;136(pt 2):494–507.
10. Davidson AE, et al. Novel deletion of lysine 7 expands the clinical, histopathological and genetic spectrum of TPM2-related myopathies. *Brain.* 2013;136(pt 2):508–521.
11. Tajsharghi H, et al. Congenital myopathy with nemaline rods and cap structures caused by a mutation in the beta-tropomyosin gene (TPM2). *Arch Neurol.* 2007;64(9):1334–1338.
12. Clarke NF, et al. Cap disease due to mutation of the beta-tropomyosin gene (TPM2). *Neuromuscul Disord.* 2009;19(5):348–351.
13. Ohlsson M, et al. New morphologic and genetic findings in cap disease associated with beta-tropomyosin (TPM2) mutations. *Neurology.* 2008;71(23):1896–1901.
14. Clarke NF, North KN. Congenital fiber type disproportion--30 years on. *J neuropathol Exp Neurol.* 2003;62(10):977–989.
15. Bamshad M, et al. Arthrogryposis: a review and update. *J Bone Joint Surg Am.* 2009;91(suppl 4):40–46.
16. Sung SS, et al. Mutations in genes encoding fast-twitch contractile proteins cause distal arthrogryposis syndromes. *Am J Hum Genet.* 2003;72(3):681–690.
17. Li S, et al. Novel mutations in TPM2 and PIEZO2 are responsible for distal arthrogryposis (DA) 2B and mild DA in two Chinese families. *BMC Med Genet.* 2018;19(1):179.
18. Tajsharghi H, et al. Distal arthrogryposis and muscle weakness associated with a beta-tropomyosin mutation. *Neurology.* 2007;68(10):772–775.
19. Marttila M, et al. Mutation update and genotype-phenotype correlations of novel and previously described mutations in TPM2 and TPM3 causing congenital myopathies. *Hum Mutat.* 2014;35(7):779–790.
20. Mroczek M, et al. A novel TPM2 gene splice-site mutation causes severe congenital myopathy with arthrogryposis and dysmorphic features. *J Appl Genet.* 2017;58(2):199–203.
21. Tajsharghi H, et al. Myopathies associated with β -tropomyosin mutations. *Neuromuscul Disord.* 2012;22(11):923–933.
22. Vogt J, et al. A recurrent pathogenic variant in TPM2 reveals further phenotypic and genetic heterogeneity in multiple pterygium syndrome-related disorders. *Clin Genet.* 2020;97(6):908–914.
23. Morgan NV, et al. Mutations in the embryonal subunit of the acetylcholine receptor (CHRNA3) cause lethal and Escobar variants of multiple pterygium syndrome. *Am J Hum Genet.* 2006;79(2):390–395.
24. Bamshad M, et al. A gene for distal arthrogryposis type I maps to the pericentromeric region of chromosome 9. *Am J Hum Genet.* 1994;55(6):1153–1158.
25. Monnier N, et al. Absence of beta-tropomyosin is a new cause of Escobar syndrome associated with nemaline myopathy. *Neuromuscul Disord.* 2009;19(2):118–123.
26. Marston S, et al. Mutations in repeating structural motifs of tropomyosin cause gain of function in skeletal muscle myopathy patients. *Hum Mol Genet.* 2013;22(24):4978–4987.
27. Karpicheva OE, et al. Looking for targets to restore the contractile function in congenital myopathy caused by Gln¹⁴⁷ pro tropomyosin. *Int J Mol Sci.* 2020;21(20):7590.
28. Borovikov YS, et al. The molecular mechanism of muscle dysfunction associated with the R133W mutation in Tpm2.2. *Biochem Biophys Res Commun.* 2020;523(1):258–262.
29. Avrova SV, et al. The reason for the low Ca²⁺-sensitivity of thin filaments associated with the Glu41Lys mutation in the TPM2 gene is “freezing” of tropomyosin near the outer domain of actin and inhibition of actin monomer switching off during the ATPase cycle. *Biochem Biophys Res Commun.* 2018;502(2):209–214.
30. Borovikov YS, et al. The reason for a high Ca²⁺-sensitivity associated with Arg91Gly substitution in TPM2 gene is the abnormal behavior and high flexibility of tropomyosin during the ATPase cycle. *Biochem Biophys Res Commun.* 2017;494(3–4):681–686.

31. Borovikov YS, et al. Molecular mechanisms of dysfunction of muscle fibres associated with Glu139 deletion in TPM2 gene. *Sci Rep*. 2017;7(1):16797.
32. Ochala J, et al. A myopathy-linked tropomyosin mutation severely alters thin filament conformational changes during activation. *Proc Natl Acad Sci U S A*. 2010;107(21):9807–9812.
33. Marttila M, et al. Abnormal actin binding of aberrant β -tropomyosins is a molecular cause of muscle weakness in TPM2-related nemaline and cap myopathy. *Biochem J*. 2012;442(1):231–239.
34. Borovikov YS, et al. Aberrant movement of β -tropomyosin associated with congenital myopathy causes defective response of myosin heads and actin during the ATPase cycle. *Arch Biochem Biophys*. 2015;577–578:11–23.
35. Matyushenko AM, et al. Structural and functional properties of $\alpha\beta$ -heterodimers of tropomyosin with myopathic mutations Q147P and K49del in the β -chain. *Biochem Biophys Res Commun*. 2019;508(3):934–939.
36. Shibata T, et al. Tropomyosin 2 heterozygous knockout in mice using CRISPR-Cas9 system displays the inhibition of injury-induced epithelial-mesenchymal transition, and lens opacity. *Mech Ageing Dev*. 2018;171:24–30.
37. Guo Y, et al. Drosophila myosin mutants model the disparate severity of type 1 and type 2B distal arthrogryposis and indicate an enhanced actin affinity mechanism. *Skelet Muscle*. 2020;10(1):24.
38. Demontis F, Perrimon N. Integration of Insulin receptor/Foxo signaling and dMyc activity during muscle growth regulates body size in *Drosophila*. *Development*. 2009;136(6):983–993.
39. Littleton JT, et al. Mutational analysis of *Drosophila* synaptotagmin demonstrates its essential role in Ca(2+)-activated neurotransmitter release. *Cell*. 1993;74(6):1125–1134.
40. Paululat A, et al. Fusion from myoblasts to myotubes is dependent on the rolling stone gene (rost) of *Drosophila*. *Development*. 1995;121(8):2611–2620.
41. Hakeda S, et al. Requirements of Kettin, a giant muscle protein highly conserved in overall structure in evolution, for normal muscle function, viability, and flight activity of *Drosophila*. *J Cell Biol*. 2000;148(1):101–114.
42. Brooks DS, et al. Optimization of wrMTrck to monitor *Drosophila* larval locomotor activity. *J Insect Physiol*. 2016;93–94:11–17.
43. Blau HM, et al. Cytoplasmic activation of human nuclear genes in stable heterocaryons. *Cell*. 1983;32(4):1171–1180.
44. Abdul-Hussein S, et al. Phenotypes of myopathy-related beta-tropomyosin mutants in human and mouse tissue cultures. *PLoS One*. 2013;8(9):e72396.
45. Whittle J, et al. MYH3-associated distal arthrogryposis zebrafish model is normalized with para-aminobenzotriazole. *EMBO Mol Med*. 2020;12(11):e12356.
46. Jing L, Zon LI. Zebrafish as a model for normal and malignant hematopoiesis. *Dis Model Mech*. 2011;4(4):433–438.
47. Lehtokari VL, et al. Cap disease caused by heterozygous deletion of the beta-tropomyosin gene TPM2. *Neuromuscul Disord*. 2007;17(6):433–442.
48. Jin JY, et al. A mutation of beta-tropomyosin gene in a Chinese family with distal arthrogryposis type I. *Int J Clin Exp Pathol*. 2017;10(11):11137–11142.
49. Robaszekiewicz K, et al. Tropomyosin isoforms differentially modulate the regulation of actin filament polymerization and depolymerization by cofilins. *FEBS J*. 2016;283(4):723–737.
50. Janco M, et al. The impact of tropomyosins on actin filament assembly is isoform specific. *Bioarchitecture*. 2016;6(4):61–75.
51. Kardon G. Muscle and tendon morphogenesis in the avian hind limb. *Development*. 1998;125(20):4019–4032.
52. Dennis MJ, et al. Development of neuromuscular junctions in rat embryos. *Dev Biol*. 1981;81(2):266–279.
53. Keenan SR, Currie PD. The developmental phases of zebrafish myogenesis. *J Dev Biol*. 2019;7(2):E12.
54. Cortés F, et al. Cadherin-mediated differential cell adhesion controls slow muscle cell migration in the developing zebrafish myotome. *Dev Cell*. 2003;5(6):865–876.
55. Chen EH, Olson EN. Towards a molecular pathway for myoblast fusion in *Drosophila*. *Trends Cell Biol*. 2004;14(8):452–460.
56. Chong JX, et al. Mutations in MYLPP cause a novel segmental amyoplasia that manifests as distal arthrogryposis. *Am J Hum Genet*. 2020;107(2):293–310.
57. Clarke NF, et al. Mutations in TPM2 and congenital fibre type disproportion. *Neuromuscul Disord*. 2012;22(11):955–958.
58. Johnson AN, et al. Post-transcriptional regulation of myotube elongation and myogenesis by Hoi Polloi. *Development*. 2013;140(17):3645–3656.
59. Lilly B, et al. Requirement of MADS domain transcription factor D-MEF2 for muscle formation in *Drosophila*. *Science*. 1995;267(5198):688–693.
60. Sadler B, et al. Rare and de novo duplications containing SHOX in clubfoot. *J Med Genet*. 2020;57(12):851–857.
61. Chagovetz AA, et al. Interactions among ryanodine receptor isoforms contribute to muscle fiber type development and function. *Dis Model Mech*. 2019;13(2):dmm038844.
62. Śliwńska M, et al. Functional effects of substitutions I92T and V95A in actin-binding period 3 of tropomyosin. *Biochim Biophys Acta Proteins Proteom*. 2018;1866(4):558–568.
63. Ochala J, et al. Defective regulation of contractile function in muscle fibres carrying an E41K beta-tropomyosin mutation. *J Physiol*. 2008;586(12):2993–3004.
64. Robinson P, et al. Mutations in fast skeletal troponin I, troponin T, and beta-tropomyosin that cause distal arthrogryposis all increase contractile function. *FASEB J*. 2007;21(3):896–905.
65. Ko JM, et al. First Korean family with a mutation in TPM2 associated with Sheldon-Hall syndrome. *J Korean Med Sci*. 2013;28(5):780–783.
66. Jarraya M, et al. Whole-body muscle MRI in a series of patients with congenital myopathy related to TPM2 gene mutations. *Neuromuscul Disord*. 2012;22(suppl 2):S137–S147.